Market closedNon-fractional
Insmed/INSM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Insmed
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Ticker
INSM
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Bridgewater, United States
Employees
912
Website
www.insmed.com
Insmed Metrics
BasicAdvanced
$12B
Market cap
-
P/E ratio
-$5.21
EPS
0.93
Beta
-
Dividend rate
Price and volume
Market cap
$12B
Beta
0.93
Financial strength
Current ratio
1.803
Quick ratio
1.504
Long term debt to equity
-244.44
Total debt to equity
-294.245
Interest coverage (TTM)
-8.67%
Management effectiveness
Return on assets (TTM)
-31.79%
Return on equity (TTM)
293.21%
Valuation
Price to revenue (TTM)
33.876
Price to book
-23.84
Price to tangible book (TTM)
-17.54
Price to free cash flow (TTM)
-18.159
Growth
Revenue change (TTM)
22.54%
Earnings per share change (TTM)
21.42%
3-year revenue growth (CAGR)
23.43%
3-year earnings per share growth (CAGR)
18.08%
What the Analysts think about Insmed
Analyst Ratings
Majority rating from 17 analysts.
Insmed Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$76M
-9.69%
Net income
-$157M
-15.59%
Profit margin
-207.94%
-6.54%
Insmed Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.78
-$1.11
-$1.28
-$1.06
-
Expected
-$1.13
-$1.13
-$1.15
-$1.23
-$1.13
Surprise
57.40%
-1.94%
11.68%
-13.89%
-
Insmed News
AllArticlesVideos
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewsWire·3 weeks ago
Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference
PRNewsWire·3 weeks ago
Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025
PRNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Insmed stock?
Insmed (INSM) has a market cap of $12B as of July 27, 2024.
What is the P/E ratio for Insmed stock?
The price to earnings (P/E) ratio for Insmed (INSM) stock is 0 as of July 27, 2024.
Does Insmed stock pay dividends?
No, Insmed (INSM) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Insmed dividend payment date?
Insmed (INSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Insmed?
Insmed (INSM) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Insmed stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.